menu
    • menu
    [{"orgOrder":0,"company":"ValiRx","sponsor":"Physiomics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide","year":"2021","type":"Collaboration","leadProduct":"VAL201","moa":"Androgen activated SRC kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ValiRx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ValiRx \/ ValiRx","highestDevelopmentStatusID":"7","companyTruncated":"ValiRx \/ ValiRx"},{"orgOrder":0,"company":"ValiRx","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"UNITED KINGDOM","productType":"Peptide","year":"2020","type":"Agreement","leadProduct":"VAL301","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"ValiRx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ValiRx \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"ValiRx \/ Undisclosed"},{"orgOrder":0,"company":"ValiRx","sponsor":"Kalos Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Agreement","leadProduct":"KTH-222","moa":"MAPK","graph1":"Oncology","graph2":"Preclinical","graph3":"ValiRx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ValiRx \/ ValiRx","highestDevelopmentStatusID":"4","companyTruncated":"ValiRx \/ ValiRx"},{"orgOrder":0,"company":"ValiRx","sponsor":"Kalos Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Termination","leadProduct":"KTH-222","moa":"MAPK","graph1":"Oncology","graph2":"Preclinical","graph3":"ValiRx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ValiRx \/ ValiRx","highestDevelopmentStatusID":"4","companyTruncated":"ValiRx \/ ValiRx"}]

    Find Clinical Drug Pipeline Developments & Deals by ValiRx

    Menu

    ValiRx

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ValiRx

                            United Kingdom arrow
                            Vitafoods
                            Not Confirmed

                            ValiRx

                            United Kingdom arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KTH-222

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Kalos Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            KTH222 Evaluation Agreement Concluded

                            Details : ValiRx had entered into an agreement with Kalos Therapeutics, whereby ValiRx would perform a range of preclinical evaluation experiments to determine whether to enter a full licensing agreement for KTH222.

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            May 27, 2021

                            Lead Product(s) : KTH-222

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Kalos Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ValiRx

                            United Kingdom arrow
                            Vitafoods
                            Not Confirmed

                            ValiRx

                            United Kingdom arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VAL201

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Physiomics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            ValiRx plc Extension of Collaboration Agreement

                            Details : ValiRx will benefit from Physiomics' expertise in modelling the effects of prostate cancer care, as well as the latest version of its Virtual TumourTM technology, which will be used to extract useful information from the additional data provided by the V...

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            February 17, 2021

                            Lead Product(s) : VAL201

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Physiomics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ValiRx

                            United Kingdom arrow
                            Vitafoods
                            Not Confirmed

                            ValiRx

                            United Kingdom arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KTH-222

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Kalos Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            ValiRx PLC Signs an Agreement with Kalos Therapeutics

                            Details : Under the terms of the agreement, ValiRx has the right to perform a defined series of preclinical, cell-based assays to consider the benefit of using KTH222 in combination with standard of care treatment, Paclitaxel.

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            October 11, 2020

                            Lead Product(s) : KTH-222

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Kalos Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ValiRx

                            United Kingdom arrow
                            Vitafoods
                            Not Confirmed

                            ValiRx

                            United Kingdom arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VAL301

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            ValiRx Signs Drug Transfer Agreement With Japanese Pharma Firm

                            Details : Agreement signed with the company will see VAL301 evaluated for the purpose of contemplating a potential future license for the treatment of endometriosis.

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            January 05, 2020

                            Lead Product(s) : VAL301

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            ValiRx

                            United Kingdom arrow
                            Vitafoods
                            Not Confirmed

                            ValiRx

                            United Kingdom arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VAL201

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dose Finding Safety Study of VAL201 in Cancer Patients

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            October 31, 2014

                            Lead Product(s) : VAL201

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth